Many investors view the healthcare sector as a safe haven when the stock market is turbulent. Here are three no-brainer ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Vertex Pharmaceuticals has dominated the cystic fibrosis (CF) market and is now expanding into new, high-growth areas. The ...

The US pharmaceutical sector is experiencing a distinct trend never seen before with large American pharma companies continually looking for medicines in China.

Shares of Vertex Pharmaceuticals Incorporated VRTX rose 2.4% on its cystic fibrosis drug Alyftrek getting approval in the United Kingdom. Shares of Tesla, Inc. TSLA plummeted 15.4% on the broad-based ...

Vertex Pharmaceuticals’ triple combination cystic fibrosis (CF) treatment has been approved by the Medicines and Healthcare ...

The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its ...

The Nasdaq Composite Index ( ^IXIC -4.00%) is now squarely in correction territory. But stock market corrections have one key ...

UK MHRA approves Vertex’s Alyftrek, a once-daily next-in-class CFTR modulator to treat cystic fibrosis: London Monday, March 10, 2025, 10:00 Hrs [IST] Vertex Pharmaceuticals, a ...

What's considered excellent revenue growth depends on the industry. With that context in mind, consider that Eli Lilly's ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Vertex Pharmaceuticals (NasdaqGS:VRTX) announced that its cystic fibrosis treatment, ALYFTREK®, had received regulatory approval from the UK's MHRA, a significant milestone in expanding its market ...